India, Sept. 22 -- Alkem Laboratories announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer.Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab. In the pivotal phase 3 clinical trial, Alkem's pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator.Accessibility of pertuzumab in India has remained a significant challenge and only limited HER2-postive breast cancer patients are able to use it in their treatment due to cost barriers. By bringing an affordable pertuzumab biosimilar, backed by research, regul...